# The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis

> **NCT05813561** · PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 332 (actual)

## Conditions studied

- Reflux Esophagitis

## Interventions

- **DRUG:** DWP14012

## Key facts

- **NCT ID:** NCT05813561
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-30
- **Primary completion:** 2022-07-23
- **Final completion:** 2023-02-17
- **Target enrollment:** 332 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05813561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05813561, "The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05813561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*